Vyndaqel (Tafamidis) – Treatment for Transthyretin Familial Amyloid Polyneuropathy

Vyndaqel is approved by the European Commission and also awarded orphan drug designation in the US. Image courtesy of Pfizer.



  • Vyndaqel
  • Vyndaqel for FAP
  • Pfizer Vyndaqel